Published in J Urol on April 01, 2007
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
The growing teratoma syndrome: Current review of the literature. Indian J Urol (2009) 1.32
Disseminated ovarian Growing Teratoma Syndrome: a case -report highlighting surgical safety issues. Facts Views Vis Obgyn (2014) 0.95
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study. Eur J Nucl Med Mol Imaging (2010) 0.78
Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors. Ther Adv Urol (2009) 0.78
Growing teratoma syndrome: a rare case report and review of the literature. Case Rep Obstet Gynecol (2012) 0.76
Growing teratoma syndrome. Case Rep Urol (2014) 0.76
Klinefelter Syndrome with Poor Risk Extragonadal Germ Cell Tumor. Urol Case Rep (2016) 0.75
Oligometastatic Growing Teratoma Syndrome: A Case for an Aggressive Surgical Approach. Curr Urol (2016) 0.75
Scrotal recurrence of germ cell tumour in a non-violated scrotum. Can Urol Assoc J (2016) 0.75
Growing Teratoma Syndrome. Indian J Surg Oncol (2016) 0.75
Growing Teratoma Syndrome After Treatment of a Nonseminomatous Germ Cell Tumor: A Case Report and a Review of Literature. Urol Case Rep (2013) 0.75
Growing Teratoma Syndrome Secondary to Ovarian Giant Immature Teratoma in an Adolescent Girl: A Case Report and Literature Review. Medicine (Baltimore) (2016) 0.75
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Epidermal electronics. Science (2011) 8.65
Regions of strong coupling between soil moisture and precipitation. Science (2004) 5.96
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol (2013) 5.07
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol (2013) 4.04
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol (2010) 3.20
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer (2009) 3.12
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Urology (2010) 2.99
Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer (2010) 2.75
Focus on bladder cancer. Cancer Cell (2004) 2.59
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J (2011) 2.50
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41
Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol (2011) 2.39
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 2.21
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol (2009) 2.18
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
Contemporary management of locally invasive bladder cancer. Oncology (Williston Park) (2011) 2.06
Applications of beta-mixture models in bioinformatics. Bioinformatics (2005) 2.04
An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol (2004) 1.99
Alcohol consumption and visual impairment in a rural Northern Chinese population. Ophthalmic Epidemiol (2014) 1.98
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev (2009) 1.93
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 1.90
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood (2009) 1.86
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int (2011) 1.85
Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol Cell Biol (2006) 1.85
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther (2009) 1.80
A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res (2012) 1.79
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer (2010) 1.76
Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am (2007) 1.75
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep (2010) 1.74
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A (2007) 1.73
The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol (2008) 1.73
VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics (2012) 1.71
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int (2006) 1.70
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer (2007) 1.69
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol (2009) 1.68
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 1.67
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol (2012) 1.65
Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol (2007) 1.65
Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family. J Mol Med (Berl) (2005) 1.63
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology (2006) 1.63
Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol (2006) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer (2007) 1.56
Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther (2010) 1.55
Oxygen reduction on well-defined core-shell nanocatalysts: particle size, facet, and Pt shell thickness effects. J Am Chem Soc (2009) 1.55
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol (2008) 1.54
Gq signaling causes glomerular injury by activating TRPC6. J Clin Invest (2015) 1.54
Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol (2008) 1.54
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol (2010) 1.53
The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol (2011) 1.53
Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol (2010) 1.52
An integrated high-throughput data acquisition system for biological solution X-ray scattering studies. J Synchrotron Radiat (2012) 1.52